<DOC>
	<DOCNO>NCT01180465</DOCNO>
	<brief_summary>LIPO-102 evaluation treatment abdominal adiposity</brief_summary>
	<brief_title>A Dose-ranging , Study Safety Efficacy Subcutaneous Injections LIPO-102 Compared With Placebo Reduction Abdominal Subcutaneous Adiposity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>18 50 year old inclusive Localized area abdominal subcutaneous adiposity Grade 3 PPNS CPNS BMI &lt; 25kg/m sq Stable diet exercise body weight Prior treatment abdominal subcutaneous adipose tissue Females within 12 month postpardum Known hypersensitivity drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Treatment abdominal adiposity</keyword>
</DOC>